Vaxart's Revenue Soars on Government Contracts, Losses Narrow

TL;DR

Vaxart's massive government contract revenue surge is a game-changer, but watch their cash burn and R&D spend closely as they race to commercialize their oral vaccines.

AI Summary

Vaxart, Inc. (VXRT) reported a significant increase in revenue from government contracts for the six months ended June 30, 2025, reaching $59.03 million, a substantial rise from $7.96 million in the same period of 2024. Total revenue for the six months ended June 30, 2025, was $60.61 million, up from $8.58 million in 2024. Despite this revenue growth, the company's net loss for the six months ended June 30, 2025, was $30.58 million, an improvement from a net loss of $40.88 million in the prior year. Research and development expenses surged to $80.48 million for the six months ended June 30, 2025, compared to $36.49 million in 2024, reflecting increased clinical trial activities. The company's cash and cash equivalents decreased from $25.23 million at December 31, 2024, to $20.11 million at June 30, 2025. Vaxart implemented a 21% workforce reduction in May and June 2025 to decrease operating costs and expects its cash runway to extend into the first quarter of 2026, contingent on continued execution of the 2024 ATI-RRPV Contract.

Why It Matters

Vaxart's substantial increase in government contract revenue to $59.03 million signals strong external validation and funding for its oral vaccine platform, which is critical for a clinical-stage biotech with no product sales. This influx of capital, despite ongoing net losses, provides a lifeline for investors concerned about liquidity, especially given the company's cash and cash equivalents of $20.11 million as of June 30, 2025. The 21% workforce reduction, while a cost-saving measure, highlights the competitive pressures and the need for efficient capital deployment in the biotech sector. For customers, continued funding could accelerate the development of Vaxart's norovirus and SARS-CoV-2 oral vaccine candidates, potentially offering novel, easier-to-administer vaccine options.

Risk Assessment

Risk Level: high — Vaxart's cash, cash equivalents, and short-term investments of $26.3 million as of June 30, 2025, are not sufficient to fund planned operations for 12 months, indicating a significant going concern risk. The company is dependent on raising additional capital, and there is no assurance of success, as explicitly stated in Note 2. Furthermore, the substantial increase in research and development expenses to $80.48 million for the six months ended June 30, 2025, compared to $36.49 million in 2024, underscores a high burn rate for a company without product sales.

Analyst Insight

Investors should closely monitor Vaxart's progress in securing additional capital and the milestones achieved under the 2024 ATI-RRPV Contract. Given the high risk and reliance on future funding, consider this a speculative investment and evaluate the potential for dilution from future equity offerings.

Financial Highlights

debt To Equity

3.99

revenue

$60.61M

operating Margin

-50.3%

total Assets

$164.09M

total Debt

$131.21M

net Income

-$30.58M

eps

-$0.13

gross Margin

N/A

cash Position

$20.11M

revenue Growth

+605.5%

Revenue Breakdown

Key Numbers

• $59.03M — Revenue from government contracts (Increased from $7.96 million for the six months ended June 30, 2024, to $59.03 million for the six months ended June 30, 2025.)
• $30.58M — Net loss (Improved from a net loss of $40.88 million for the six months ended June 30, 2024, to $30.58 million for the six months ended June 30, 2025.)
• $80.48M — Research and development expenses (Increased from $36.49 million for the six months ended June 30, 2024, to $80.48 million for the six months ended June 30, 2025.)
• $20.11M — Cash and cash equivalents (Decreased from $25.23 million at December 31, 2024, to $20.11 million at June 30, 2025.)
• 21% — Workforce reduction (Percentage of workforce reduced in May and June 2025 to decrease operating costs.)
• 228,919,064 — Shares of common stock outstanding (As of August 6, 2025.)
• $0.1M — Net proceeds from March 2025 ATM (From the sale of 382,700 shares during the six months ended June 30, 2025.)
• $37.5M — Net proceeds from June 2024 Offering (From the sale of 50,000,000 shares at $0.80 per share.)
• $9.9M — Net proceeds from 2024 Securities Purchase Agreement (From the sale of 15,384,615 shares at $0.65 per share.)
• $26.3M — Cash, cash equivalents and short-term investments (Total as of June 30, 2025, insufficient to fund 12 months of operations.)

Key Players & Entities

• Vaxart, Inc. (company) — registrant
• Citizens JMP Securities, LLC (company) — Manager for March 2025 ATM
• B. Riley Securities, Inc. (company) — Manager for March 2025 ATM
• Oppenheimer & Co. Inc. (company) — underwriter for June 2024 offering
• RA Capital Healthcare Fund, L.P. (company) — purchaser in 2024 Securities Purchase Agreement
• Biomedical Advanced Research and Development Authority (regulator) — primary source of government funding
• U.S. Department of Health and Human Services (regulator) — parent department of BARDA
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Cash Burn and Runway Uncertainty [high — financial]: The company's cash and cash equivalents decreased to $20.11 million as of June 30, 2025, from $25.23 million at December 31, 2024. While a workforce reduction and continued execution of the 2024 ATI-RRPV Contract are expected to extend the cash runway into Q1 2026, this remains contingent on contract performance.
• Dependence on Government Contracts [high — operational]: A substantial portion of revenue, $59.03 million for the six months ended June 30, 2025, is derived from government contracts. The company's financial stability is heavily reliant on the continued execution and funding of these contracts, particularly the 2024 ATI-RRPV Contract.
• Increased R&D Spending [medium — operational]: Research and development expenses surged to $80.48 million for the six months ended June 30, 2025, from $36.49 million in the prior year. This significant increase is attributed to expanded clinical trial activities, which, while necessary for product development, place a considerable strain on financial resources.
• Negative Working Capital [medium — financial]: As of June 30, 2025, the company has $70.38 million in current assets and $117.88 million in current liabilities, resulting in negative working capital. This is largely due to significant deferred government revenue ($65.38 million) and other accrued current liabilities ($35.73 million).
• Workforce Reduction [medium — operational]: The company implemented a 21% workforce reduction in May and June 2025 to decrease operating costs. While intended to improve financial efficiency, such reductions can impact operational capacity and employee morale.
• Clinical Trial Success and Regulatory Approval [high — regulatory]: The company's success is contingent on the successful completion of clinical trials and subsequent regulatory approvals for its vaccine candidates. Delays or failures in these processes can significantly impact future revenue and market viability.

Industry Context

Vaxart operates in the biopharmaceutical industry, specifically focusing on vaccine development. The sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Competition is intense, with major pharmaceutical companies and numerous smaller biotechs vying for market share and government funding. Recent trends include increased focus on novel delivery methods (like oral vaccines) and preparedness for emerging infectious diseases.

Regulatory Implications

The company's primary regulatory risks stem from the clinical trial process and the need for FDA approval for its vaccine candidates. Delays, adverse trial results, or manufacturing issues could impede progress. Furthermore, reliance on government contracts introduces compliance requirements and potential shifts in government funding priorities.

What Investors Should Do

1. Monitor government contract performance and milestones.
2. Evaluate R&D spending efficiency and clinical trial progress.
3. Assess cash burn rate and runway projections.
4. Analyze the impact of workforce reduction on operations.

Key Dates

• 2025-06-30: Six Months Ended — Reporting period showing significant revenue growth from government contracts and increased R&D spending, alongside a reduced net loss.
• 2025-05-01: Workforce Reduction Initiated — Company began a 21% workforce reduction to control operating costs, impacting its operational structure.
• 2025-03-01: March 2025 ATM Offering — Raised $0.1 million in net proceeds, indicating ongoing efforts to secure capital through equity sales.
• 2024-06-30: Six Months Ended — Prior year period for comparison, showing significantly lower revenue and R&D expenses.
• 2024-06-01: June 2024 Offering — Raised $37.5 million, a significant capital infusion that impacts the company's financial position and runway.
• 2024-01-01: 2024 Securities Purchase Agreement — Raised $9.9 million, contributing to the company's cash reserves.

Glossary

Unbilled receivable from government contracts

Revenue that has been earned but not yet invoiced to the government entity. (Highlights a significant portion of earned revenue ($36.78 million) that has not yet been converted to cash, impacting immediate liquidity.)

Deferred government revenue

Payments received from the government for services or goods that have not yet been delivered or earned. (Represents a large current liability ($65.38 million), indicating obligations to the government that will be recognized as revenue over time.)

Right-of-use assets, net

The value of assets recognized under lease accounting standards, representing the right to use an asset over a lease term. (Indicates the company's long-term lease commitments, such as for office or lab space.)

Accumulated deficit

The total net losses of a company since its inception that have not been offset by net income. (Shows the company's historical unprofitability, with a deficit of $507.10 million as of June 30, 2025.)

ATI-RRPV Contract

A specific government contract, likely related to advanced technologies or research and development for a respiratory virus vaccine. (Crucial for the company's near-term revenue and cash runway, as its continued execution is explicitly linked to financial projections.)

ATM

At-The-Market offering, a type of equity offering where shares are sold on the open market at prevailing prices. (Indicates a method used by the company to raise capital opportunistically, as seen with the March 2025 offering.)

Year-Over-Year Comparison

Vaxart has experienced a dramatic increase in revenue, primarily from government contracts, soaring from $8.58 million in the first six months of 2024 to $60.61 million in the same period of 2025. This revenue surge has led to a narrower net loss, improving from $40.88 million to $30.58 million. However, this growth is accompanied by a substantial increase in R&D expenses, which more than doubled from $36.49 million to $80.48 million, reflecting intensified clinical trial activities. The company's cash position has also decreased, highlighting the significant investment required for its development programs.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value VXRT * Indicate by chec

Filing Documents

• vxrt20250630_10q.htm (10-Q) — 1931KB
• ex_848901.htm (EX-10.1) — 24KB
• ex_829072.htm (EX-31.1) — 16KB
• ex_829073.htm (EX-31.2) — 16KB
• ex_829074.htm (EX-32.1) — 12KB
• logosml.jpg (GRAPHIC) — 4KB
• 0001437749-25-026514.txt ( ) — 7934KB
• vxrt-20250630.xsd (EX-101.SCH) — 62KB
• vxrt-20250630_cal.xml (EX-101.CAL) — 45KB
• vxrt-20250630_def.xml (EX-101.DEF) — 416KB
• vxrt-20250630_lab.xml (EX-101.LAB) — 368KB
• vxrt-20250630_pre.xml (EX-101.PRE) — 449KB
• vxrt20250630_10q_htm.xml (XML) — 1337KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 5 Notes to the Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 4.

Controls and Procedures

Controls and Procedures 38 Part II OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A.

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 3. Defaults Upon Senior Securities 41 Item 4. Mine Safety Disclosures 41 Item 5. Other Information 41 Item 6. Exhibits 42

SIGNATURES

SIGNATURES 44 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") for the quarterly period ended June 30, 2025, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as "anticipate," "assume," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "will," "would," and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described herein under "Item 1A. Risk Factors." and those described in our Annual Report on Form 10-K for the year ended December 31, 2024, under "Item 1A. Risk Factors." You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements.

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements VAXART, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts ) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 20,111 $ 25,229 Short-term investments 6,160 26,494 Accounts receivable 4,281 5,761 Unbilled receivable from government contracts 36,781 6,208 Prepaid expenses and other current assets 3,046 4,568 Total current assets 70,379 68,260 Property and equipment, net 6,926 8,705 Prepaid clinical services, long-term 60,116 60,116 Right-of-use assets, net 18,137 20,404 Intangible assets, net 3,192 3,557 Goodwill 4,508 4,508 Other long-term assets 827 839 Total assets $ 164,085 $ 166,389 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 10,611 $ 6,963 Deferred government revenue 65,377 65,400 Other accrued current liabilities 35,727 11,378 Current portion of operating lease liability 3,486 3,077 Current portion of liability related to sale of future royalties 2,677 4,060 Total current liabilities 117,878 90,878 Operating lease liability, net of current portion 12,627 14,449 Liability related to sale of future royalties, net of current portion 230 1,698 Other long-term liabilities 472 439 Total liabilities 131,207 107,464 Commitments and contingencies (Note 7) Stockholders' equity: Preferred stock: $ 0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock: $ 0.0001 par value; 350,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 229,417,137 shares issued and 228,912,563 shares outstanding as of June 30, 2025 and 228,203,822 shares issued and 227,774,275 shares outstanding as of December 31, 2024 23 23 Additional paid-in capital 540,328 535,770 Treasury stock at cost, 504,574 shares as of June 30, 2025 and 429,547 share

View Full Filing

View this 10-Q filing on SEC EDGAR